These observations, together with the results of the ProtectT study showing that prostate cancer-specific mortality was low in PSA detected cases after 15 years, regardless of treatment strategy (active surveillance, radiotherapy or radical prostatectomy) [18], point to other explanatory factors than PSA testing for the initial years of decline in mortality. This evidence concerns the gene KLK3 and prostate cancer.